Ground breaking pancreatic cancer trial that aims to match patients with targeted and effective treatment for tumours has successfully recruited its 100th patient.
Run by Precision-Panc, a research programme and clinical trials project led by the University of Glasgow with major funding from Cancer Research UK, the trial brings a precision medicine approach to pancreatic cancer treatment for the first time in the UK.
Pancreatic cancer is the fifth most common cause of cancer death in UK
Pancreatic cancer is the fifth most common cause of cancer death in the UK with a 5-year survival rate of less than 3%. Around 9,800 people are diagnosed with pancreatic cancer per year and around 9,000 people die.
Precision-Panc Master Protocol Trials
In December 2017 Precision-Panc began working alongside NHS Greater Glasgow and Clyde Health Board to recruit suitable pancreatic cancer patients to their pancreatic cancer trial at Glasgow Royal Infirmary.
This project success has seen means it has been rolled out to 16 sites across the UK, offering potential treatment hope for pancreatic cancer patients nationwide.
Rach patient undergoes tumour biopsy to obtain material that is then used for molecular profiling at the Glasgow Precision Oncology Laboratory (GPOL) within the University of Glasgow. The results may then be used to help match patients to the most appropriate, currently available clinical trial.
Linking clinical data with the patient’s unique molecular profiling data
This ability to link clinical data with patient’s unique molecular profiling data enables rapid new discoveries, and enhances the delivery of precision medicine to current and future patients.
Professor Andrew Biankin, Chief Investigator of Precision Panc and Regius Chair of Surgery and Director of the University of Glasgow Wolfson Wohl Cancer Research Centre, said:
“I am extremely proud of what we have been able to achieve so far with Precision Panc. Recruiting the 100th patient is a milestone for us and signals our ability to make real changes to the lives and survival rates of patients with pancreatic cancer.
“The success we have achieved so far – including opening 17 sites across the country – is testament to what we are able to achieve and deliver for patients as a team.”
The overall aim is to make precision medicine a reality for more people with pancreatic cancer through building up knowledge ultimately allows clinicians to match patients with suitable treatment or clinical trial for them.
The project aims to facilitate drug development, and ultimately new drug approval, allowing access and improving survival in patients with pancreatic cancer.
Dr Ian Walker, Director of Clinical Research at Cancer Research UK, said:
“To make real progress in improving survival for people with pancreatic cancer, we need to understand which drugs will be most likely to provide benefit for individual patients.
“While overall survival from cancer has doubled over the last 40 years, pancreatic cancer has only seen little improvement, and too many people die from the disease each year. Innovative studies like Precision-Panc are vital to changing the outlook for these patients and we look forward to seeing how it continues to progress.”
About Precision-Panc and the PRIMUS Trials
Three clinical trials will recruit a total of 658 pancreatic cancer patients with scope to add more trials in the future. Each clinical trial will test new drugs and combinations of drugs tailored to match specific patients.
This is an ambitious programme of research that seeks to uncover the molecular profile of individual patients with pancreatic cancer, to learn more about the disease and to pave the way for patients entering clinical trials in a way that matches their tumour biology to the type of treatment.
It is composed of a network of clinical trials aimed to find the right trial for the right patient matching patients to treatments most likely to work for their type of pancreatic cancer. It is designed to be comprehensive with a faster turnaround time than traditional clinical trials while advancing discovery through science and ultimately changing patient outcomes in this disease.
Precision-Panc is a collaborative effort between clinicians, scientists and various other experts with key partnerships between the NHS GGC Biorepository, Molecular Genetics West of Scotland Genetic Services based at the Queen Elizabeth University Hospital, the Glasgow Precision Oncology Laboratory at the Wolfson Wohl Cancer Research Center, University of Glasgow, Beatson Institute for Cancer Research, and the CRUK Clinical Trials Unit formed to carry out tissue acquisition, storage, processing, testing and analysis.
In 2017 Cancer Research UK committed £10 million investment to support Precision Panc. Other support and funding has been received from the University of Glasgow, Celgene, Wellcome Trust, Chief Scientist’s Office, Scottish Genomes Partnership, MRC/ESPRC Glasgow Molecular Pathology Node, NHS Scotland, The Howat Foundation, Pancreatic Cancer UK, The Scottish Precision Medicine Ecosystem/Stratified Medicine Scotland Innovation Centre, AstraZeneca/MedImmune, NCRI and ECMC.
Pancreatic Cancer UK (and Pancreatic Cancer Scotland) provide further critical support to the Precision-Panc network and generally to those affected by pancreatic cancer.
PRIMUS-001 (Pancreatic Cancer Individualized Multi-arm Umbrella Study) is an adaptive Phase II/III study with an integrated biomarker evaluation in patients with metastatic disease and is currently open at 11 sites around the UK.
PRIMUS-002 will aim to define biomarkers of therapeutic responsiveness in the neoadjuvant setting and opened in Glasgow in March 2019. Celgene International supports both of these studies.
Additionally, PRIMUS-003, supported by AstraZeneca, is using an immunotherapy approach and is also currently recruiting patients in the metastatic setting. If appropriate, as part of the Precision-Panc Master Protocol, patients may also be helped onto other suitable clinical trials that are already up and running across the UK.